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To the Editor, 
 Cho et al. (1) concluded that nonalcoholic steatohepatitis (NASH) might be 
independent risk factor for advanced colorectal neoplasm (ACN) and, considering the 
sequential progression from colorectal adenoma (CRA) to colorectal cancer (CRC) 
according to nonalcoholic fatty liver disease (NAFLD) histological spectrum, is an 
essential message for clinicians. Though further studies are warranted to elucidate 
the NAFLD pathophysiology associated with ACN, the authors mentioned mediators 
including insulin resistance (IR) with a proinflammatory state and gut microbiota 
dysbiosis (GM-D) playing crucial roles in NAFLD pathogenesis resulting in ACN 
development (1).  
Beyond NAFLD, the current worldwide Helicobacter pylori infection (Hp-I) 
prevalence is about 58% (varied from 39.9% to 84.2%) with increasing tendency due 
to immigrants (2); its current prevalence in Asia is about 54.7% (varied from 43.1% to 
79.5%) (3).  Moreover, GM-D- and/or Hp-I- associated metabolic syndrome (MetS) 
seems to predict NAFLD severity (4); there is a causal relation between GM and 
MetS and GM-D may play a critical role in NAFLD/ NASH pathogenesis via metabolic 
and inflammatory pathways. Moreover, GM-D-related MetS may contribute to CRC 
pathophysiology. Hp-I-related MetS is also connected with IR, the pathogenetic key 
of MetS and its related morbidity, including NAFLD and CRC (2,5). 
 Based on histology, the practical gold standard for current Hp-I diagnosis, our 
data in 50 CRC patients, 25 patients with CRA and 10 controls, showed significantly 
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higher presence of Hp-I in the CRA (68%) and CRC (84%) groups compared with 
controls (30%). Regarding the histological severity features in CRA group, presence 
of Hp-I was observed in 50% of patients with mild and 80% of patients with 
moderate/severe dysplasia (6). Likewise, presence of Hp-I in the CRC group was 
observed in 89% of patients with mild and 83% of patients with moderate/severe 
grade. Noteworthy, Hp presence was documented by immunohistochemical stain in 
CRA and CRC tissues. In addition, presence of Hp-I with accompanying 
immunohistochemical expression of CD44 -indicator of cancer stem cells and/or 
bone marrow-derived stem cells in biopsy specimens was found in a high proportion 
of CRA patients accompanied with moderate/severe dysplasia (88%) and CRC 
patients with moderate/severe degree of malignancy (91%). Comparable pictures 
were also obtained for proliferation marker Ki-67, anti-apoptotic Bcl-2 and CD45 
(assessing T and B lymphocytes locally) immunohistochemical expressions (6). 
Notably, CD44 and CD45 are also NASH key players. More specifically, 
CD44 increases the hepatic steatosis to NASH progression by controlling hepatic 
macrophage polarization (pro-inflammatory phenotype) and infiltration, thus making 
CD44 a possible therapeutic target (7). Moreover, CD44, as a stem cell marker of 
diverse malignancies, is involved in cancer progression and metastasis, including 
NAFLD-related hepatocellular carcinoma (8) as well as CRC (9).  In this respect, one 
could hypothesize that CD44 might also be involved in NAFLD-related CRC 
progression and metastasis (10), and thus further studies are needed to elucidate 
this field. 
Therefore, because active Hp-I with concomitant NAFLD, MetS and/or other MB-D, 
might be involved in CRA-CRC sequence, Hp eradication might benefit these 
pathologies and thus large-scale studies are required. 
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